3.82
前日終値:
$3.76
開ける:
$3.76
24時間の取引高:
2.61M
Relative Volume:
1.08
時価総額:
$1.16B
収益:
$248.37M
当期純損益:
$11.74M
株価収益率:
76.40
EPS:
0.05
ネットキャッシュフロー:
$18.24M
1週間 パフォーマンス:
-5.21%
1か月 パフォーマンス:
+1.33%
6か月 パフォーマンス:
-36.75%
1年 パフォーマンス:
-33.10%
Mannkind Corp Stock (MNKD) Company Profile
MNKD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MNKD
Mannkind Corp
|
3.82 | 1.22B | 248.37M | 11.74M | 18.24M | 0.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-16 | 再開されました | H.C. Wainwright | Buy |
2025-04-10 | 開始されました | Mizuho | Outperform |
2025-02-10 | 開始されました | Wedbush | Outperform |
2024-12-20 | 開始されました | Wells Fargo | Overweight |
2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2024-09-09 | 再開されました | Leerink Partners | Outperform |
2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
2023-10-10 | 開始されました | Wedbush | Outperform |
2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
2019-12-24 | 開始されました | Oppenheimer | Outperform |
2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
2019-05-14 | 開始されました | BTIG Research | Buy |
2019-03-04 | 開始されました | SVB Leerink | Outperform |
2019-02-22 | 開始されました | SVB Leerink | Outperform |
2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
2017-10-10 | 開始されました | H.C. Wainwright | Buy |
2017-10-06 | 繰り返されました | Maxim Group | Buy |
2017-08-11 | 開始されました | Maxim Group | Buy |
2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
2015-05-11 | 繰り返されました | MLV & Co | Hold |
2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
What analysts say about MannKind Corporation stockFree Stock Market Knowledge Sharing - Autocar Professional
What drives MannKind Corporation stock priceExtraordinary profit generation - Autocar Professional
MannKind Corporation Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright - Defense World
Mannkind director Binder sells $296945 in shares By Investing.com - Investing.com South Africa
H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com
What makes MannKind Corporation stock price move sharplyLow Risk Scalping Alerts - Newser
How MannKind Corporation stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser
High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance
Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Insider Monkey
13 Best Healthcare Stocks to Buy Under $10 - Insider Monkey
Wedbush Remains Bullish on MannKind Corporation (MNKD) - Insider Monkey
13 Stocks Under $5 With High Upside Potential - Insider Monkey
MannKind Corp stock hits 52-week low at $3.63 - Investing.com
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000 Value Index - MarketScreener
Today In SCV History: June 27, 2014 – Valencia Company Given FDA Approval For Inhaled Insulin - KHTS Radio
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Insider Monkey
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia
MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
Mannkind Corp (MNKD) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq
Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio
MannKind corp director Steven Binder sells $375,875 in stock By Investing.com - Investing.com UK
MannKind EVP David Thomson sells shares worth $150,597 By Investing.com - Investing.com India
MannKind EVP David Thomson sells shares worth $150,597 - Investing.com
MannKind corp director Steven Binder sells $375,875 in stock - Investing.com
MannKind CMO steps down, transition plan set - Investing.com
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):